Key Documents
NIH Biosketch available Online
Robert Negrin
- Professor, Medicine - Division: Blood and Marrow Transplantation
- Member, Cancer Center
Contact Information
- Clinical Offices
Blood and Marrow Transplantation 875 Blake Wilbur Dr Clinic E Stanford, CA 94305-5820 Telephone Work (650) 723-0822 Fax (650) 725-8950
- Academic Offices
Personal Information Email negrs@stanford.edu Tel (650) 723-0822Administrative Contact Sara Clark Tel Work 725-4959Not for medical emergencies or patient use
Clinical Focus
- Cancer > Bone Marrow Transplant
- Cancer > Hematology
- Blood and Marrow Transplantation
- Hematology
Administrative Appointments
- Medical Director, Clinical Bone Marrow Transplantation Laboratory , (1990– present )
- Division Chief, Blood and Marrow Transplant Program, Stanford University , (2000– present )
Honors and Awards
- Fellowship, Damon Runyon-Walter Winchell Cancer Fund (1988-1991)
- Fellow, Jose Carreras International Leukemia Foundation (1993-1996)
- President, International Society of Cellular Therapy (2000-2002)
- Distinguished Clinical Scientist Award, Doris Duke Foundation (2004)
- President, American Society of Blood and Marrow Transplantation (2006-2007)
Professional Education
- Board Certification: Hematology, American Board of Internal Medicine (1992)
- Board Certification: Internal Medicine, American Board of Internal Medicine (1987)
- SUMC - Graduate Medical Education (1987) CA
- SUMC - Graduate Medical Education (1987) CA
- Stanford University School of Medicine (1985) CA
- Harvard Medical School (1984) MA
- BA, Univ. California, Berkeley Biochemistry (1977)
- MD, Harvard Medical School Medicine (1984)
Postdoctoral Advisees
Graduate & Fellowship Program Affiliations
Community & International Work
- Volunteer More »
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.
- Consulting: Baxter Inc
Research Interests
Research projects in our laboratory are aimed at studying the biology of cell populations capable of inducing or suppressing graft vs host disease as well as cells capable of promoting a graft vs tumor effect. In particular we are studying:
1) The clinical utility of expanded cytotoxic cells for immunotherapy. We have developed animal models utilizing mice with severe combined immunodeficiency (SCID) which will accept human tumor cells or murine model systems of syngeneic and allogeneic transplantation. In some instances the tumor cells are transfected with the bioluminescent marker luciferase so that the tumor cell growth can be quantitatively tracked in living animals. Using these model system we are studying the clinical efficacy of the expanded cytotoxic cells.
2) The interaction between the cytotoxic effector cells and a variety of tumor cell targets is under study. The role of granzyme/perforin and fas mediated pathways as well as the cell surface molecule NKG2D in cytotoxicity is under study.
3) We are exploring the biological impact of phenotypically defined populations of regulatory T cells on graft vs host disease and graft vs tumor reactions.
4) We are utilizing bioluminescent techniques to study these complex biological processes by either labelling the tumor or effector cell populations with the light emitting luciferase gene such that small numbers of cells can be tracked non-invasively, sensively and quantitatively.
Clinical Trials
- Bone Marrow Grafting for Leukemia and Lymphoma Recruiting
- Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation Recruiting
- Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
- A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft versus Host Disease Recruiting
- Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
- Allogeneic Hematopoietic Cell Transplantation Using TLI/ATG for Older Patients with Hematologic Malignancies Recruiting
- Allogeneic Transplantation From Related Haploidentical Donors in Older Patients with Indolent Hematologic Malignancies Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
- Chronic GVHD Cohort Protocol Recruiting
- Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Recruiting
- Defibrotide for Hematopoietic SCT Patients With Severe Hepatic VOD: a Treatment IND Study Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Recruiting
- Imatinib Mesylate and Nilotinib After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Recruiting
- NMDP Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
- Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG Recruiting
- Ph II of Non-myeloablative Allgnc Trnsplnt Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Recruiting
- Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL Recruiting
- Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT) Recruiting
- Sirolimus & Mycophenolate Mofetil as GVHD prophylaxis in Myeloablative, Matched Related Donor HCT Recruiting
- Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease Recruiting
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Recruiting
- Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma No longer recruiting
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies No longer recruiting
- Transplantation for Patients with Chronic Lymphocytic Leukemia No longer recruiting
- A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation Completed
- Allo BMT in Advanced Leukemia or High Grade Lymphoma No longer recruiting
- Allogeneic Transplantation for Patients with Acute Leukemia or CML No longer recruiting
- Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission No longer recruiting
- Autologous Stem Cell Rescue for Primary Amyloidosis No longer recruiting
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients No longer recruiting
- High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma No longer recruiting
- Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma Completed
- Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders No longer recruiting
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies No longer recruiting
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients No longer recruiting
- Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors No longer recruiting
Publications
- J Immunol. 2009; (5): 3219-28
- Bone Marrow Transplant. 2009;
- Int J Cancer. 2009; (1): 239-44
- Blood. 2009; (5): 1099-109
- Biol Blood Marrow Transplant. 2009; (7): 765-76
- Blood. 2008; (2): 945-53
- Blood. 2008; (5): 2919-28
- Blood. 2008; (1): 453-62
- Blood. 2008; (3): 903-9
- Biol Blood Marrow Transplant. 2008; (7): 741-7
- J Immunol. 2008; (6): 3811-7
- Blood. 2008; (6): 2563-74
- Blood. 2007; (6): 2649-56
- Blood. 2007; (13): 4588-98
- Biol Blood Marrow Transplant. 2007; (12): 1427-38
- Blood. 2007; (5): 2225-33
- Blood. 2006; (1): 390-9
- Biol Blood Marrow Transplant. 2006; (7): 703-11
- Nat Rev Immunol. 2006; (6): 484-90
- Biol Blood Marrow Transplant. 2006; (10): 995-1009
- Science. 2006; (5768): 1780-4
- Curr Stem Cell Res Ther. 2006; (2): 203-12
- Clin Cancer Res. 2006; (6): 1859-67
- Annu Rev Med. 2005; 509-38
- Transplantation. 2005; (1): 134-9
- Blood. 2005; (3): 1113-22
- N Engl J Med. 2005; (13): 1321-31
- Biol Blood Marrow Transplant. 2005; (3): 181-7
- Am J Pathol. 2005; (5): 1321-31
- J Immunol. 2005; (12): 7819-28
- Nat Med. 2003; (9): 1144-50
- Blood. 2003; (2): 640-8
- Ann Hematol. 2002; S44-5
- J Clin Immunol. 2002; (3): 131-6
- Cancer Res. 2002; (20): 5785-91
- Eur J Cancer. 2002; (16): 2128-36
- J Cell Biochem Suppl. 2002; 239-48
- Biol Blood Marrow Transplant. 2001; (5): 294-301
- Cancer. 2001; (12): 2205-13
- Biol Blood Marrow Transplant. 2001; (9): 503-12
- Exp Hematol. 2001; (12): 1353-60
- Biol Blood Marrow Transplant. 2001; (10): 532-42
- Biol Blood Marrow Transplant. 2001; (10): 552-60
- Biol Blood Marrow Transplant. 2001; (4): 216-22
- Blood. 2001; (2): 404-9
- Immunol Lett. 2001; (3): 169-73
- Blood. 2001; (10): 2923-31
- Neoplasia. 2000 Jan-Apr; (1-2): 41-52
- Biol Blood Marrow Transplant. 2000; (5A): 555-62
- Biol Blood Marrow Transplant. 2000; (5): 506-12
- Cancer Immunol Immunother. 2000; (6): 335-45
- Biol Blood Marrow Transplant. 2000; (1): 58-69
- Biol Blood Marrow Transplant. 2000; (3): 262-71
- Biol Blood Marrow Transplant. 2000; (3A): 352-8
- Biol Blood Marrow Transplant. 2000; (4): 387-94
- Blood. 2000; (12): 3827-37
- Biol Blood Marrow Transplant. 1999; (5): 299-305
- Clin Cancer Res. 1999; (11): 3411-8
- Neoplasia. 1999; (4): 303-10
- Biol Blood Marrow Transplant. 1999; (5): 285-91
- Proc Natl Acad Sci U S A. 1999; (21): 12044-9
- Hematol Oncol. 1998; (3): 87-100
- Blood. 1998; (9): 3318-27
- Curr Opin Hematol. 1998; (6): 488-93
- Blood. 1997; (3): 801-13
- J Clin Oncol. 1997; (1): 18-25
- Blood. 1997; (7): 2586-95
- Biol Blood Marrow Transplant. 1997; (3): 113-21
- Biol Blood Marrow Transplant. 1997; (6): 324-30
- Bone Marrow Transplant. 1996; S31-3
- Biol Blood Marrow Transplant. 1996; (2): 76-85
- Biol Blood Marrow Transplant. 1996; (2): 86-92
- Blood. 1996; (10): 4076-81
- Cancer. 1996; (12): 2502-9
- Clin Cancer Res. 1996; (3): 457-70
- Exp Hematol. 1995; (9): 1024-9
- Blood. 1995; (11): 3334-41
- Anesth Analg. 1995; (4): 770-2
- Leukemia. 1995; (1): 30-9
- Cancer. 1995; (5): 860-8
- Cancer. 1995; (6): 1354-9
- Blood. 1995; (9): 3493-9
- J Immunol. 1994; (4): 1687-96
- Blood. 1994; (5): 1680-4
- J Clin Oncol. 1994; (12): 2552-8
- Blood. 1994; (10): 2823-8
- Bone Marrow Transplant. 1994; S9-10
- Cell Immunol. 1994; (1): 95-110
- J Clin Oncol. 1994; (5): 1021-7
- Exp Hematol. 1993; (13): 1673-9
- N Engl J Med. 1993; (17): 1225-30
- Leukemia. 1993; (10): 1491-5
- Blood. 1993; (3): 737-43
- Drug Saf. 1993; (6): 457-68
- Blood. 1993; (8): 2031-5
- Blood. 1993; (2): 319-23
- Curr Opin Immunol. 1992; (5): 567-70
- Blood. 1992; (3): 825-30
- Transfusion. 1992; (1): 42-5
- Adv Pharmacol. 1992; 263-96
- J Hematother. 1992; (4): 361-8
- J Exp Med. 1991; (1): 139-49
- Ann Oncol. 1991; 47-50
- Blood. 1991; (3): 654-60
- Blood. 1990; (7): 1299-307
- Bone Marrow Transplant. 1990; 121-6
- Blood. 1990; (1): 36-43
- Leukemia. 1990; (3): 193-202
- Cancer Surv. 1990; (1): 199-212
- Clin Transpl. 1990; 157-63
- Int J Cell Cloning. 1990; 293-300; discussion 300-2
- Prog Clin Biol Res. 1990; 151-61
- Ann Intern Med. 1989; (12): 976-84
- J Immunol Methods. 1989; (1-2): 185-9
- Chest. 1987; (4): 621-4